IMUX

Immunic (IMUX)

Immunic Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:IMUX

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/03/03	20:30	PR Newswire (US)	Immunic to Participate in Scientific and Investor Conferences in March	NASDAQ:IMUX	Immunic Inc
2025/02/26	20:30	PR Newswire (US)	Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis	NASDAQ:IMUX	Immunic Inc
2025/02/20	21:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMUX	Immunic Inc
2025/02/20	21:30	PR Newswire (US)	Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing	NASDAQ:IMUX	Immunic Inc
2025/02/15	00:16	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:IMUX	Immunic Inc
2025/02/12	23:44	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:IMUX	Immunic Inc
2025/02/04	20:30	PR Newswire (US)	Immunic to Participate in Investor and Scientific Conferences in February	NASDAQ:IMUX	Immunic Inc
2025/01/13	22:32	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMUX	Immunic Inc
2025/01/07	20:30	PR Newswire (US)	Immunic Highlights 2024 Accomplishments and Upcoming Milestones	NASDAQ:IMUX	Immunic Inc
2024/12/19	06:36	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMUX	Immunic Inc
2024/12/09	22:30	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:IMUX	Immunic Inc
2024/12/07	07:32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMUX	Immunic Inc
2024/12/07	07:31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMUX	Immunic Inc
2024/12/07	07:31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMUX	Immunic Inc
2024/12/07	07:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMUX	Immunic Inc
2024/12/07	07:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMUX	Immunic Inc
2024/11/26	20:30	PR Newswire (US)	Immunic, Inc. to Participate in Investor Conference in December	NASDAQ:IMUX	Immunic Inc
2024/11/15	07:33	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:IMUX	Immunic Inc
2024/11/14	20:58	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:IMUX	Immunic Inc
2024/11/14	04:13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMUX	Immunic Inc
2024/11/13	20:30	PR Newswire (US)	Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology	NASDAQ:IMUX	Immunic Inc
2024/11/12	23:31	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:IMUX	Immunic Inc
2024/11/07	21:04	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IMUX	Immunic Inc
2024/11/07	20:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMUX	Immunic Inc
2024/11/07	20:30	PR Newswire (US)	Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:IMUX	Immunic Inc
2024/10/31	19:30	PR Newswire (US)	Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update	NASDAQ:IMUX	Immunic Inc
2024/10/29	19:30	PR Newswire (US)	Immunic to Participate in Industry, Scientific and Investor Conferences in November	NASDAQ:IMUX	Immunic Inc
2024/10/22	19:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMUX	Immunic Inc
2024/10/22	19:30	PR Newswire (US)	Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis	NASDAQ:IMUX	Immunic Inc
2024/09/18	19:30	PR Newswire (US)	Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis	NASDAQ:IMUX	Immunic Inc